

# Enriqueta Felip

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4221164/publications.pdf>

Version: 2024-02-01

232  
papers

52,511  
citations

10389

72  
h-index

1676

214  
g-index

239  
all docs

239  
docs citations

239  
times ranked

35629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	7.1	50
2	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. <i>Cancers</i> , 2022, 14, 641.	3.7	7
3	Role of ctDNA in Breast Cancer. <i>Cancers</i> , 2022, 14, 310.	3.7	40
4	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
5	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	2.3	7
6	Encorafenib plus binimetinib in patients with <i>BRAF</i> <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	2.4	9
7	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
8	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	10.7	50
9	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3305.	3.7	11
10	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	2.9	30
11	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
12	Olmутinib in T790M <sup>+</sup> positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor tyrosine kinase inhibitor therapy: A global, phase 2 study. <i>Cancer</i> , 2021, 127, 1407-1416.	4.1	17
13	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	3.2	4
14	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	10.7	773
15	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
16	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ 2 and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. <i>Targeted Oncology</i> , 2021, 16, 435-446.	3.6	21
17	A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8588-TPS8588.	1.6	3
18	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37

#	ARTICLE	IF	CITATIONS
19	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1â€Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	1.1	85
20	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	2.8	11
21	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	2.0	7
22	Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. <i>Trends in Microbiology</i> , 2021, 29, 836-848.	7.7	29
23	Brigatinib Versus Crizotinib in ALK Inhibitorâ€Naïve Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	1.1	156
24	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	2.8	1
25	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 1344-1357.	13.7	689
26	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 125, 1561-1569.	6.4	4
27	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertionâ€Positive Metastatic Nonâ€Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	7.1	160
28	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021, 22, 1669-1680.	10.7	73
29	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
30	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	1.1	17
31	First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	27.0	592
32	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€Naïve ALK-Positive Nonâ€Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	1.6	224
33	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	9.4	151
34	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. <i>ESMO Open</i> , 2020, 5, e000820.	4.5	96
35	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020, 4, 505-513.	3.0	10
36	Tepotinib in Nonâ€Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	27.0	500

#	ARTICLE	IF	CITATIONS
37	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
38	Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. <i>Cancers</i> , 2020, 12, 713.	3.7	14
39	SAMHD1 Is a Modulator of Nucleos(t)ide Analoguesâ€™ Efficacy. <i>Proceedings (mdpi)</i> , 2020, 50, 58.	0.2	0
40	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 55-65.	3.6	86
41	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 561-572.	10.7	47
42	The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. <i>Cancer Treatment Reviews</i> , 2020, 87, 102022.	7.7	51
43	New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102990.	4.4	12
44	Atezolizumab for First-Line Treatment of PD-L1â€™Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	27.0	959
45	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9504-9504.	1.6	91
46	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1â€™positive advanced nonâ€™small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	2.0	189
47	Real-world data on T-DM1 efficacy â€™ results of a single-center retrospective study of HER2-positive breast cancer patients. <i>Scientific Reports</i> , 2019, 9, 12760.	3.3	17
48	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 74-79.	2.0	14
49	Assessment of a New ROS1 Immunohistochemistry Cloneâ€™(SP384)â€™for the Identification of ROS1 Rearrangements in Patients with Nonâ€™Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
50	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.6	24
51	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	2.0	24
52	Five-Year Overall Survival for Patients With Advanced Nonâ€™Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	1.6	811
53	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 888-899.	5.6	50
54	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	1.1	78

#	ARTICLE	IF	CITATIONS
55	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. <i>Antiviral Research</i> , 2019, 168, 18-27.	4.1	8
56	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	1.1	99
57	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1 Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	1.1	50
58	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	3.7	101
59	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.6	14
60	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	10.7	137
61	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	17
62	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1370-1379.	1.6	282
63	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 341-352.	4.2	82
64	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	3.7	37
65	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000532.	4.5	13
66	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. <i>Thorax</i> , 2019, 74, 371-379.	5.6	9
67	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.	2.6	12
68	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128.	2.8	50
69	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.	1.5	6
70	A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. <i>Journal of Clinical Oncology</i> , 2019, 37, 9098-9098.	1.6	16
71	A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2667-TPS2667.	1.6	9
72	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9114-TPS9114.	1.6	6

#	ARTICLE	IF	CITATIONS
73	MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.. Journal of Clinical Oncology, 2019, 37, TPS9123-TPS9123.	1.6	0
74	Activity of HSP90 Inhibitor in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 110, 914-917.	6.3	16
75	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
76	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	2.6	7
77	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	1.1	66
78	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 576-584.	1.1	62
79	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 351.	7.1	599
80	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer, 2018, 19, 74-83.e11.	2.6	28
81	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3101-3109.	1.6	252
82	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258.	1.6	308
83	COX-2 inhibitors in NSCLC: never-ending story or misplaced?. Translational Lung Cancer Research, 2018, 7, S191-S194.	2.8	4
84	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	1.1	133
85	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	10.7	587
86	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
87	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	27.0	691
88	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. Journal of Thoracic Oncology, 2018, 13, 874-876.	1.1	5
89	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer, 2018, 101, 201-209.	2.8	41
90	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. JAMA Oncology, 2018, 4, 1189.	7.1	53

#	ARTICLE	IF	CITATIONS
91	Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 3078-3078.	1.6	5
92	Avelumab (anti-â€œPD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.. Journal of Clinical Oncology, 2018, 36, 9008-9008.	1.6	47
93	Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2018, 36, TPS9117-TPS9117.	1.6	1
94	Monitoring <i>EGFR</i>-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	1.8	8
95	Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.. Journal of Clinical Oncology, 2018, 36, 9101-9101.	1.6	0
96	Osimertinib in Pretreated T790M-Positive Advanced Non-â€œSmall-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296.	1.6	470
97	Single-cell transcriptome conservation in cryopreserved cells and tissues. Genome Biology, 2017, 18, 45.	8.8	134
98	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 435-444.	10.7	172
99	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-â€œSmall Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.9	327
100	First-Line Nivolumab in Stage IV or Recurrent Non-â€œSmall-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
101	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 874-886.	10.7	453
102	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer, 2017, 109, 101-108.	2.0	25
103	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 2017, 23, 5406-5415.	7.0	29
104	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews, 2017, 55, 181-189.	7.7	12
105	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. Cancer Investigation, 2017, 35, 358-365.	1.3	9
106	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	7.0	66
107	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncology, The, 2017, 18, 1590-1599.	10.7	535
108	Osimertinib-related skin and mucosal adverse events. Cancer Treatment and Research Communications, 2017, 12, 53-55.	1.7	1

#	ARTICLE	IF	CITATIONS
109	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
110	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017, 8, 410.	12.8	117
111	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
112	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and OAK). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
113	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	2.8	9
114	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
115	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	1.6	216
116	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. <i>Breathe</i> , 2016, 12, 249-255.	1.3	18
117	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1479-1489.	3.1	10
118	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
119	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). <i>Lung Cancer</i> , 2016, 99, 94-101.	2.0	11
120	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	1.6	316
121	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , 2016, 387, 1540-1550.	13.7	5,456
122	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
123	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 801-807.	1.1	21
124	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , 2016, 17, 452-463.	10.7	418
125	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016, 17, 161-168.	2.6	13
126	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 767-776.	2.3	118



#	ARTICLE	IF	CITATIONS
127	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 212-223.	10.7	158
128	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016, 36, 6647-6654.	1.1	9
129	El c�ncer de pulm�n en mujeres. <i>Arbor</i> , 2015, 191, a235.	0.3	0
130	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , 2015, 6, 8839.	12.8	605
131	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	2.0	40
132	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	10.7	389
133	AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699.	27.0	1,802
134	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333.	2.6	65
135	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	7.1	224
136	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	1.2	308
137	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015, 21, 560-562.	30.7	1,280
138	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	27.0	7,973
139	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	1.1	138
140	Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3034-3034.	1.6	3
141	Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). <i>Journal of Clinical Oncology</i> , 2015, 33, 8002-8002.	1.6	8
142	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. <i>Journal of Clinical Oncology</i> , 2015, 33, 8013-8013.	1.6	18
143	Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. <i>Journal of Clinical Oncology</i> , 2015, 33, 8018-8018.	1.6	27
144	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. <i>Journal of Clinical Oncology</i> , 2015, 33, 8026-8026.	1.6	12

#	ARTICLE	IF	CITATIONS
145	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	13
146	Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.. Journal of Clinical Oncology, 2015, 33, TPS2620-TPS2620.	1.6	5
147	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	74
148	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2015, 10, e0121071.	2.5	185
149	Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2015, 33, e18540-e18540.	1.6	0
150	Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.. Journal of Clinical Oncology, 2015, 33, 8100-8100.	1.6	0
151	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	1.2	210
152	Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Experimental Hematology and Oncology, 2014, 3, 26.	5.0	29
153	Ganitumab for the treatment of small-cell lung cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1423-1432.	4.1	2
154	Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors. Journal of Thoracic Oncology, 2014, 9, 316-323.	1.1	44
155	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	1.2	246
156	Lungscape: Resected Non-â€œSmall-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	1.1	31
157	Ceritinib in <i>ALK</i>-Rearranged Non-â€œSmall-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197.	27.0	1,367
158	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	1.2	410
159	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i>-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research, 2014, 20, 2001-2010.	7.0	215
160	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	2.0	19
161	Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2014, 32, 7569-7569.	1.6	10
162	First-line crizotinib versus pemetrexedâ€œcisplatin or pemetrexedâ€œcarboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Journal of Clinical Oncology, 2014, 32, 8002-8002.	1.6	44

#	ARTICLE	IF	CITATIONS
163	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8003-8003.	1.6	24
164	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8009-8009.	1.6	81
165	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. Journal of Clinical Oncology, 2014, 32, 8017-8017.	1.6	31
166	Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8046-8046.	1.6	2
167	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	1.6	22
168	Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8078-8078.	1.6	7
169	Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).. Journal of Clinical Oncology, 2014, 32, 8079-8079.	1.6	4
170	Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS8118-TPS8118.	1.6	6
171	Multicenter, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. Journal of Clinical Oncology, 2014, 32, TPS8120-TPS8120.	1.6	3
172	Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology, 2014, 32, 8072-8072.	1.6	0
173	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. Journal of Clinical Oncology, 2014, 32, 11105-11105.	1.6	0
174	The HALO study: A phase III of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, TPS2632-TPS2632.	1.6	0
175	Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer, 2013, 82, 375-382.	2.0	29
176	Phase III study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal of Cancer, 2013, 49, 1815-1824.	2.8	18
177	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1529-1537.	1.1	33
178	Adjuvant treatment of resected nonsmall cell lung cancer. Current Opinion in Oncology, 2013, 25, 115-120.	2.4	14
179	Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. Journal of Clinical Oncology, 2013, 31, 1997-2003.	1.6	572
180	Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1. European Respiratory Journal, 2013, 42, 568-571.	6.7	23

#	ARTICLE	IF	CITATIONS
181	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	9.4	43
182	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. <i>Scientific Reports</i> , 2013, 3, 3544.	3.3	45
183	Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e52261.	2.5	68
184	Women in Oncology: Progress, Challenges, and Keys to Success. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 448-455.	3.8	4
185	Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GCEP-GOAL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2581-2581.	1.6	3
186	Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013, 5, E35-7.	1.4	3
187	HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. <i>Translational Lung Cancer Research</i> , 2013, 2, 122-7.	2.8	43
188	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 398-402.	2.8	10
189	Adjuvant Chemotherapy: Feasibility in the Elderly and Patient Selection. , 2013, , 165-172.		0
190	Is There a Role for Neoadjuvant Chemotherapy in Older Patients?. , 2013, , 141-150.		0
191	ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11027-11027.	1.6	0
192	Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8070-8070.	1.6	0
193	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. <i>Translational Lung Cancer Research</i> , 2013, 2, E13-6.	2.8	0
194	Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390). <i>Journal of Thoracic Oncology</i> , 2012, 7, 203-211.	1.1	70
195	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	10.7	4,943
196	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 432-441.	2.6	19
197	Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Española De Patología</i> , 2012, 45, 14-28.	0.2	9
198	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , 2012, 6, 15-26.	4.6	66

#	ARTICLE	IF	CITATIONS
199	PI3K Pathway in NSCLC. <i>Frontiers in Oncology</i> , 2012, 1, 55.	2.8	7
200	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012, 14, 338-349.	2.4	35
201	Brain metastases: the need for a more tailored approach in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2012, 14, 1-2.	2.4	0
202	Never-smoking women with lung cancer from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1531-1531.	1.6	1
203	First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3007-3007.	1.6	29
204	EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7522-7522.	1.6	17
205	Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7542-7542.	1.6	2
206	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7543-7543.	1.6	28
207	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12000-e12000.	1.6	1
208	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12012-e12012.	1.6	3
209	GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7544-7544.	1.6	0
210	Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7041-7041.	1.6	0
211	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1223-1231.	3.1	28
212	Tissue sampling in lung cancer: A review in light of the MERIT experience. <i>Lung Cancer</i> , 2011, 74, 1-6.	2.0	40
213	Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. <i>Lung Cancer</i> , 2011, 74, 544-548.	2.0	1
214	Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2011, 12, 172-179.	2.6	171
215	Adjuvant Therapy in Non-Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. <i>Clinical Lung Cancer</i> , 2011, 12, 261-271.	2.6	32
216	Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-2.	3.0	2

#	ARTICLE	IF	CITATIONS
217	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. <i>Oncotarget</i> , 2011, 2, 165-177.	1.8	52
218	Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2010, 12, 829-835.	2.4	3
219	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	1.6	351
220	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3131-3137.	1.6	136
221	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. <i>Lung Cancer</i> , 2010, 70, 180-187.	2.0	41
222	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.	2.4	14
223	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <i>Lung Cancer</i> , 2009, 66, 257-261.	2.0	16
224	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	2.8	39
225	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 3867-3874.	7.0	73
226	Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 579-585.	2.0	12
227	Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 261-268.	3.1	24
228	Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). <i>Drugs of Today</i> , 2006, 42, 147.	1.1	17
229	Clinical Significance of Hypoxia-Inducible Factor-1 $\alpha$ Messenger RNA Expression in Locally Advanced Non-Small-Cell Lung Cancer After Platinum Agent and Gemcitabine Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2005, 6, 299-303.	2.6	5
230	Chemotherapy in resectable non-small cell lung cancer. , 2004, 6, 52-56.		0
231	A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non-Small-Cell Lung Cancers. <i>Journal of Clinical Oncology</i> , 1999, 17, 2100-2100.	1.6	475
232	Rociletinib-related bilateral cataract. <i>Precision Cancer Medicine</i> , 0, 1, 3-3.	1.8	0